(WASHINGTON) -- Health experts will now be able to save time when trying to determine whether Staphylococcus aureus infections in patients are methicillin resistant (MRSA) or methicillin susceptible (MSSA), as the U.S. Food and Drug Administration (FDA) announced on Friday that it has cleared a test that will allow a speed-up in the process.
There are various types of Staphylococci bacteria, some of which are easily treated with antibiotics and some that are resistant to this treatment, such as MRSA.
The FDA has cleared the KeyPath MRSA/MSSA Blood Culture Test for use by doctors, with officials saying that the test makes it possible to determine whether bacteria in a patient’s positive blood culture sample are MRSA or MSSA within about five hours.
“This not only saves time in diagnosing potentially life-threatening infections but also allows health care professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics Device Evaluation and Safety in the FDA’s Center for Devices and Radiological Health.
Copyright 2011 ABC News Radio